Skip to main content
Top
Published in: Breast Cancer Research 1/2018

Open Access 01-12-2018 | Correction

Correction to: Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in luminal B breast cancer

Authors: Benjamin A. Katchman, I. Tolgay Ocal, Heather E. Cunliffe, Yu-Hui Chang, Galen Hostetter, Aprill Watanabe, Janine LoBello, Douglas F. Lake

Published in: Breast Cancer Research | Issue 1/2018

Login to get access

Excerpt

After the publication of this work [1], an error was noticed in Fig. 4a. The micrograph image sh528 was accidentally duplicated. We apologize for this error and have replaced it with the correct figure below. This does not affect any of the interpretations or conclusions of the article.
Literature
1.
go back to reference Lake FD, et al. Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype, and correlates with a poor prognosis in luminal B breast cancer. Breast Cancer Res. 2013;15(2):R28.CrossRefPubMedPubMedCentral Lake FD, et al. Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype, and correlates with a poor prognosis in luminal B breast cancer. Breast Cancer Res. 2013;15(2):R28.CrossRefPubMedPubMedCentral
Metadata
Title
Correction to: Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in luminal B breast cancer
Authors
Benjamin A. Katchman
I. Tolgay Ocal
Heather E. Cunliffe
Yu-Hui Chang
Galen Hostetter
Aprill Watanabe
Janine LoBello
Douglas F. Lake
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2018
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-018-0998-7

Other articles of this Issue 1/2018

Breast Cancer Research 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine